Conclusions: Our findings highlight ZNF217 as a promising therapeutic target for the treatment of high-risk B-ALL, such as those carrying MLL-rearrangements or BCR-ABL fusion. This evidence concerns the gene ZNF217 and acute lymphoblastic leukemia.